The Asian oncology market: tough challenges but promising prospects
This article was originally published in SRA
Executive Summary
The market for oncology products is stronger in Asia than in more developed parts of the world, but companies still face many challenges getting their cancer therapies to market. With a focus on Taiwan, South Korea and China, Questa Lin reports on the key areas of stakeholder influence, the pricing and reimbursement environment and possible changes in the field of health technology assessment.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.